Departamento de Farmacologia, Centro de Ciências Biológicas, Universidade Federal de Santa Catarina, 88049-900, Florianópolis, SC, Brazil.
Mol Immunol. 2013 Jul;54(3-4):482-92. doi: 10.1016/j.molimm.2013.01.018. Epub 2013 Mar 1.
The pentacyclic triterpene α,β-amyrin has been previously reported as an effective compound in the treatment of several inflammatory conditions. Recent evidence indicates that α,β-amyrin displayed its effects through interaction with the cannabinoid pathway. We assessed the anti-inflammatory effects of the α,β-amyrin in the dextran sulfate sodium (DSS)-induced colitis in mice and investigated whether its effects were associated with the interaction with the cannabinoid system. Our results showed that the oral preventive or therapeutic treatment with α,β-amyrin significantly reduced disease activity, body weight loss, colonic damage, as well as colonic myeloperoxidase and N-acetylglucosaminidase activities. Moreover, α,β-amyrin decreases the colonic pro-inflammatory mediators tumor necrosis factor (TNF)-α, interleukin (IL)-1β and keratinocyte-derived chemokine (CXCL1/KC), while up-regulating the IL-4 levels. Additionally, we also observed that the α,β-amyrin caused a significant reduction of the adhesion molecules mRNA expression for intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), platelet cell adhesion molecule 1 (PCAM-1), β(2)-integrin and protein expression for proliferation marker Ki67, the macrophage molecule CD68 and for adhesion molecule P-selectin. Interestingly, our results also showed that the cannabinoid receptor 1 (CB(1)), but not CB(2), pharmacological blockade significantly reversed the beneficial effects of α,β-amyrin in DSS-induced colitis. Besides, our data demonstrated that mRNA expression for both the endocannabinoid hydrolase monoglyceride lipase 1 (MGL1) and fatty acid amide hydrolase (FAAH) were significantly reduced in the colon of α,β-amyrin-treated mice. Altogether, these results suggest that the α,β-amyrin might possess potential therapeutic interest for the treatment of IBD, and also provide new insights for the underlying mechanisms.
五环三萜 α,β-桉叶醇先前已被报道为治疗几种炎症疾病的有效化合物。最近的证据表明,α,β-桉叶醇通过与大麻素途径相互作用发挥其作用。我们评估了 α,β-桉叶醇在葡聚糖硫酸钠(DSS)诱导的结肠炎中的抗炎作用,并研究了其作用是否与与大麻素系统的相互作用有关。我们的结果表明,α,β-桉叶醇的口服预防或治疗性治疗可显著减轻疾病活动度、体重减轻、结肠损伤以及结肠髓过氧化物酶和 N-乙酰氨基葡萄糖苷酶活性。此外,α,β-桉叶醇可降低结肠促炎介质肿瘤坏死因子(TNF)-α、白细胞介素(IL)-1β和角质形成细胞衍生的趋化因子(CXCL1/KC),同时上调 IL-4 水平。此外,我们还观察到,α,β-桉叶醇导致细胞间黏附分子 1(ICAM-1)、血管细胞黏附分子 1(VCAM-1)、血小板细胞黏附分子 1(PCAM-1)、β(2)-整合素和增殖标志物 Ki67 的蛋白表达的黏附分子 mRNA 表达显著减少,巨噬细胞分子 CD68 和黏附分子 P 选择素。有趣的是,我们的结果还表明,大麻素受体 1(CB(1)),而不是 CB(2),药理学阻断可显著逆转 α,β-桉叶醇在 DSS 诱导的结肠炎中的有益作用。此外,我们的数据表明,α,β-桉叶醇处理的小鼠结肠中内源性大麻素水解酶单甘油酯脂肪酶 1(MGL1)和脂肪酸酰胺水解酶(FAAH)的 mRNA 表达均显著降低。总的来说,这些结果表明 α,β-桉叶醇可能具有治疗 IBD 的潜在治疗意义,并为潜在机制提供了新的见解。